Application of fructus hippophae oil in treating or preventing abdominal aortic aneurysm

Abstract

The invention belongs to the technical field of medicine, and particularly relates to application of fructus hippophae oil in treating or preventing abdominal aortic aneurys.The application includes the steps that an AAA model is established by subcutaneously infusing Ang II through a slow release pump to induce Ldlr- / -mice, SBPO gavage intervention is carried out, and by observing the thoracico-abdominal aorta form of the mice, calculating the survival rate of the mice, calculating the AAA occurrence rate and measuring and counting the maximum diameter of the aorta of the mice, the AAA model is established; it is proved that SBPO can effectively inhibit occurrence and development of mouse abdominal aortic aneurysm, a feasible scheme is provided for treatment of abdominal aortic aneurysm diseases, and the SBPO has wide application prospects in prevention and treatment of occurrence and development of abdominal aortic aneurysm.

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical technology, and specifically relates to the application of sea buckthorn pulp oil in the treatment or prevention of abdominal aortic aneurysm. Background Art

[0002] Sea buckthorn pulp oil (SBPO) is an oil extracted from the pulp of sea buckthorn, with high food safety and rich nutrition. Currently, it is found that SBPO has functions such as regulating blood sugar, blood lipid, anti-inflammatory, regulating immunity, and anti-cancer.

[0003] Abdominal aortic aneurysm (AAA) refers to the permanent local dilation of the abdominal aorta and is a common complication of vascular diseases such as hypertension and atherosclerosis. Due to the hidden onset of AAA, it is difficult to make a clinical diagnosis in the early stage of the disease. The mortality rate is extremely high after acute rupture, and the incidence is increasing year by year. Currently, the main treatment is surgery, and there is a lack of effective therapeutic drugs. In recent years, clinically, western medicines such as angiotensin-converting enzyme inhibitors / angiotensin II receptor antagonists (ACEI / ARB), β-blockers, statins, and antibiotics have been mainly used to intervene in AAA to achieve the purpose of delaying the development of AAA.

[0004] However, the currently clinically used prevention and treatment drugs often have relatively large side effects. Therefore, seeking and developing natural drugs is of great significance for the prevention and treatment of AAA. Summary of the Invention

[0005] One object of the present invention is to provide the application of sea buckthorn pulp oil in the preparation of products for treating or preventing abdominal aortic aneurysm.

[0006] As a further improvement of the present invention, the application of sea buckthorn pulp oil as the sole active ingredient in the preparation of products for treating or preventing abdominal aortic aneurysm.

[0007] As a further improvement of the present invention, provide the application of sea buckthorn pulp oil in the preparation of drugs for treating or preventing abdominal aortic aneurysm.

[0008] As a further improvement of the present invention, the drug is made into one of the following dosage forms: tablets, capsules, granules, powders, suspensions, emulsions, powders, solutions, gels, syrups, pills, tinctures, wines, decoction extracts, lozenges, mixtures, suppositories, injections, inhalants or sprays.

[0009] Another object of the present invention is to provide a drug for treating or preventing abdominal aortic aneurysm, and its active ingredient contains sea buckthorn pulp oil.

[0010] As a further improvement of the present invention, the drug further comprises at least one pharmaceutically acceptable carrier or excipient.

[0011] In the preparation of drugs, seabuckthorn fruit oil can be administered independently or in combination with pharmaceutically acceptable carriers and excipients. The "pharmaceutically acceptable carriers or excipients" include: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, coloring agents, anti-caking agents, humectants, chelating agents, plasticizers, thickening agents, antioxidants, preservatives, stabilizers, surfactants and buffers. Those skilled in the art will understand that certain pharmaceutically acceptable excipients can be used with more than one function and with alternative functions, depending on how much of the excipient is present in the formulation and what other ingredients are present in the formulation. There are many resources available to those skilled in the art that describe pharmaceutically acceptable excipients and can be used to select suitable pharmaceutically acceptable excipients, such as books like "Chinese Pharmaceutical Yearbook" and "Pharmaceutics".

[0012] The beneficial effects of adopting the above technical solution are as follows: Seabuckthorn fruit oil has an obvious effect in the treatment or prevention of abdominal aortic aneurysm. Through experimental verification, seabuckthorn fruit oil (SBPO) can effectively inhibit the occurrence and development of abdominal aortic aneurysm in mice. The present invention provides a feasible treatment plan for abdominal aortic aneurysm diseases and has broad application prospects in the prevention and treatment of the occurrence and development of abdominal aortic aneurysm. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 It is a graph of the survival rate data of mice in Example 1 of the present invention; Figure 2 It is a graph of the AAA incidence data in Example 1 of the present invention; Figure 3 It is a representative morphological schematic diagram of the aorta in Example 1 of the present invention; Figure 4 It is a graph of the maximum diameter data of the aorta in Example 1 of the present invention; Among them, * is P＜0.05 ; *** is P＜0.001 . DETAILED DESCRIPTION OF THE EMBODIMENTS

[0014] To make the objectives, technical solutions and advantages of the present invention clearer, the present invention will be clearly and completely described below in conjunction with specific embodiments.

[0015] Seabuckthorn fruit oil was purchased from Chengde Yuhangren Alpine Plant Application Technology Co., Ltd.

[0016] Example 1 1. Breeding of experimental animals Healthy male Ldlr at 16 weeks of age were selected as experimental mice - / -Mice: Before the experiment, mice had free access to food and water. They were housed in a constant temperature and humidity environment at 23 ± 1°C and 60% air humidity, with 5 mice per cage, and were raised according to a 12 h light / dark cycle (light time: 08:30 - 20:30).

[0017] 2. Establishment of the AAA model in Ang II - implanted pump mice After one - week of adaptive feeding, the mice were randomly divided into three groups, with 7 mice in each group.

[0018] Control group: No Ang II - implanted pump. Each mouse was intragastrically administered normal saline at a dose of 10 mg / kg per day. Model group: A slow - release pump was implanted in the mice of this group. Each mouse was subcutaneously injected with Ang II at a dosage of 1000 ng / kg / min for 28 days to establish the Ldlr - / - AAA model in mice. Within 7 days before pump implantation and 28 days after pump implantation, each mouse was intragastrically administered normal saline at a dose of 10 mg / kg per day. SBPO treatment group: A slow - release pump was implanted in the mice of this group. Each mouse was subcutaneously injected with Ang II at a dosage of 1000 ng / kg / min for 28 days. Within 7 days before pump implantation and 28 days after pump implantation, each mouse was intragastrically administered SBPO at a dose of 10 mg / kg per day.

[0019] 3. Experimental results and conclusions (1) Survival analysis: During the 28 - day period of Ang II - implanted pump, the survival status of the mice was statistically analyzed for survival analysis.

[0020] Conclusion: As Figure 1 shown, the statistical results of the survival rate of the mice showed that the survival rate of the mice in the AAA model group decreased almost daily from the 22nd day after pump implantation to the 28th day. In contrast, the survival rate of the SBPO treatment group was significantly increased and the survival status was stable; indicating that SBPO can effectively reduce the mortality of AAA mice. As Figure 2 shown, by statistically analyzing the incidence of AAA, it was found that the incidence of AAA in the model - group mice was significantly higher than that in the control group ( P < 0.001), and was as high as 57.1%. While the incidence of AAA in the mice treated with SBPO was significantly reduced ( P < 0.001), more than half lower than that in the model group; indicating that SBPO can effectively reduce the incidence of AAA in Ang II - induced Ldlr - / - mice.

[0021] (2)Aortic morphology: 28 days after Ang II implantation pump, the three groups of animals were fasted but allowed to drink water for 12 h, anesthetized with 0.3% sodium pentobarbital, the heart was exposed, perfused with PBS through the heart, and then the whole thoracic and abdominal aorta was removed, fixed with 4% paraformaldehyde, and the thoracic and abdominal aorta was taken for photography 24 h later.

[0022] Conclusion: From Figure 3 The morphology of the thoracic and abdominal aorta could be clearly observed. Compared with the control group, obvious aneurysmal bulges appeared in the abdominal aorta of mice after Ang II treatment in the model group, while the degree of vascular dilation was significantly reduced after SBPO intervention and tended to be normal; it indicated that SBPO had the effect of inhibiting the formation of AAA.

[0023] (3)Quantification of the maximum aortic diameter: Image J was used to calculate the maximum abdominal aortic diameter of mice.

[0024] Conclusion: As Figure 4 shown, through the quantitative statistics of the maximum aortic diameter of the three groups of mice, it was further found that AngII induction significantly increased the maximum aortic diameter of Ldlr - / - mice compared with the control group ( P < 0.001), while SBPO intervention could effectively restore the increase in aortic diameter caused by Ang II ( P < 0.05); it was proved again that SBPO could effectively reduce the dilation of the abdominal aorta of Ldlr - / - mice induced by Ang II and inhibit the occurrence and development of abdominal aortic aneurysm.

[0025] Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments, or perform equivalent replacements on some of the technical features; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of seabuckthorn fruit oil in the preparation of a product for treating or preventing abdominal aortic aneurysm.

2. Use of seabuckthorn fruit oil as the sole active ingredient in the preparation of a product for treating or preventing abdominal aortic aneurysm.

3. The application according to claim 1 or 2, characterized in that, Use of seabuckthorn fruit oil in the preparation of a drug for treating or preventing abdominal aortic aneurysm.

4. The application according to claim 3, wherein The drug can be made into one of the following dosage forms: tablets, capsules, granules, powders, suspensions, emulsions, powders, solutions, gels, syrups, pills, tinctures, wines, decoction extracts, lozenges, mixtures, suppositories, injections, inhalants or sprays.

5. A drug for treating or preventing abdominal aortic aneurysm, characterized in that, The active ingredient contains seabuckthorn fruit oil.

6. The medicament according to claim 5, characterized in that, It also contains at least one pharmaceutically acceptable carrier or excipient.

Images